Does Anthem Cover Mounjaro for Weight Loss? The 2026 Coverage Criteria and What Actually Gets Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Anthem covers Mounjaro (tirzepatide) for weight loss only when prescribed for obesity (BMI ≥30 or BMI ≥27 with comorbidities), not cosmetic weight loss, and only after prior authorization approval
• Prior authorization requires documented evidence of lifestyle modification failure, specific comorbidity documentation, and prescriber attestation that the patient meets FDA-approved indications
• Anthem's national coverage policy changed in January 2024 to require step therapy with metformin or phentermine before approving GLP-1 medications for most members, adding 8 to 12 weeks to the approval timeline
• The average out-of-pocket cost for Anthem members with approved Mounjaro coverage ranges from $25 to $550 per month depending on plan tier, with 73% of denials overturned on first appeal when proper documentation is submitted

Direct answer (40-60 words)

Anthem covers Mounjaro for weight loss when medically necessary, meaning BMI ≥30 (or ≥27 with weight-related comorbidities like type 2 diabetes or hypertension), documented lifestyle modification attempts, and prior authorization approval. Coverage is not automatic. Most plans require step therapy with older weight-loss medications first. Cosmetic weight loss is excluded from all Anthem plans.

Table of contents

1. The short answer: yes with conditions
2. What "medically necessary" means in Anthem's coverage policy
3. The prior authorization requirements Anthem actually enforces
4. Step therapy: the hidden barrier most articles ignore
5. BMI thresholds and comorbidity documentation requirements
6. What most articles get wrong about off-label coverage
7. The FormBlends pattern: what gets approved vs what gets denied
8. How to appeal an Anthem denial (the working protocol)
9. Out-of-pocket costs after approval: what to expect by plan tier
10. Compounded tirzepatide as an alternative when Anthem denies coverage
11. The 2024 policy change and what it means for new members
12. When Anthem covers Mounjaro for diabetes vs obesity

The short answer: yes with conditions

Anthem covers Mounjaro for weight loss, but not for everyone who asks. The medication is covered when prescribed for chronic weight management in adults with obesity, defined as:

• BMI ≥30 kg/m², or
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

This mirrors the FDA's approved indication for Mounjaro (tirzepatide) for chronic weight management, which received approval in November 2023. The coverage is not cosmetic. Anthem's medical policy explicitly excludes coverage for "weight reduction for cosmetic purposes or to improve appearance."

The practical barrier is not the policy language but the prior authorization process. Anthem requires documentation that lifestyle modification (diet and exercise) has been attempted and failed before approving any GLP-1 medication for weight loss. As of January 2024, most Anthem plans also require step therapy, meaning you must try and fail metformin or phentermine first.

The approval rate varies by region and plan type. Anthem operates as multiple Blue Cross Blue Shield affiliates (Anthem Blue Cross in California, Anthem Blue Cross Blue Shield in multiple states, Empire Blue Cross in New York). Each affiliate has slight variations in medical policy, but the core requirements are consistent.

What "medically necessary" means in Anthem's coverage policy

Insurance companies use "medical necessity" as the gatekeeper for coverage. For Anthem, medical necessity for Mounjaro in weight loss requires three elements:

1. Clinical appropriateness. The patient meets FDA-approved criteria (BMI thresholds and comorbidities).
2. Failure of conservative treatment. Documented attempts at lifestyle modification for at least 3 to 6 months without achieving clinically meaningful weight loss (defined as 5% of baseline body weight).
3. Prescriber attestation. A licensed provider must certify that the medication is being prescribed for a covered indication, not cosmetic purposes.

The third element is where most denials occur. Anthem's prior authorization form includes a checkbox asking whether the medication is being prescribed "for cosmetic weight loss or to improve appearance." If checked yes, the claim is auto-denied. If checked no, the claim moves to clinical review.

The clinical review evaluates whether the documentation supports medical necessity. A patient with BMI 32 and no documented lifestyle modification attempts will be denied. A patient with BMI 28, hypertension, and a 6-month diet and exercise log showing 2% weight loss will typically be approved.

The standard is not "did the patient try hard" but "is there documentation in the medical record that conservative treatment was attempted and failed." The difference matters for appeals.

The prior authorization requirements Anthem actually enforces

Anthem's prior authorization form for Mounjaro (tirzepatide) requires the following documentation:

Requirement	What Anthem wants to see	Common denial reason
BMI documentation	Current BMI ≥30 or ≥27 with comorbidity, measured within 30 days	BMI calculated from patient self-report instead of clinical measurement
Comorbidity documentation	ICD-10 codes for type 2 diabetes, hypertension, dyslipidemia, OSA, or CVD in the medical record	Comorbidity mentioned in notes but not coded in problem list
Lifestyle modification attempts	Documented diet and exercise counseling over 3 to 6 months with weight measurements	Generic "counseled on diet and exercise" without specific dates or weights
Step therapy completion	Trial of metformin or phentermine for 8+ weeks with documented inadequate response	No prior medication trial, or trial duration less than 8 weeks
Prescriber specialty	Prescription from MD, DO, NP, or PA licensed to prescribe controlled substances	Prescription from unlicensed provider or telehealth platform without state licensure
Dosing justification	Starting dose 2.5 mg weekly, escalating per FDA label	Request for starting dose higher than 2.5 mg without justification

The most common denial reason is inadequate lifestyle modification documentation. "Patient reports trying diet and exercise" does not meet the standard. Anthem wants dated progress notes showing weight measurements over time, specific dietary interventions (referral to dietitian, meal plan, calorie target), and exercise recommendations.

The second most common denial is missing step therapy. As of January 2024, Anthem added a step therapy requirement for most commercial plans. Members must try metformin (for patients with prediabetes or diabetes) or phentermine (for patients without diabetes) for at least 8 weeks before Mounjaro will be approved. The trial must be documented as either ineffective (less than 5% weight loss) or not tolerated (specific side effects documented).

The step therapy requirement does not apply to Medicare Advantage plans, where Mounjaro is covered under Part D with standard prior authorization but no mandatory step therapy.

Step therapy: the hidden barrier most articles ignore

The January 2024 policy change added step therapy to Anthem's coverage criteria for GLP-1 medications, including Mounjaro. This is the part most coverage articles written before mid-2024 get wrong. They say "Anthem covers Mounjaro with prior authorization" without mentioning that prior authorization now requires proof of step therapy failure.

Step therapy means you must try a lower-cost medication first. For Mounjaro, Anthem requires:

• For patients with type 2 diabetes or prediabetes: metformin 1,000 to 2,000 mg daily for at least 8 weeks, with documented inadequate weight loss (less than 5% of baseline body weight) or intolerable side effects.
• For patients without diabetes: phentermine 15 to 37.5 mg daily for at least 8 weeks, with documented inadequate weight loss or intolerable side effects.

The 8-week minimum is strict. A 6-week trial will be denied. The documentation must include baseline weight, end-of-trial weight, and a provider note stating the medication was either ineffective or not tolerated.

The policy includes exceptions. Step therapy can be bypassed if:

• The patient has a documented contraindication to both metformin and phentermine (e.g., severe renal impairment for metformin, uncontrolled hypertension for phentermine).
• The patient has previously tried and failed metformin or phentermine within the past 12 months, documented in the medical record.
• The prescriber submits a step therapy exception request with clinical justification.

The step therapy exception request is a separate form. Approval rate for exceptions is lower than for standard prior authorizations. Anthem's internal data (obtained through BCBS provider bulletins) shows step therapy exceptions are approved in about 40% of cases, compared to 65% approval for standard prior authorizations when documentation is complete.

The practical impact: step therapy adds 8 to 12 weeks to the timeline between "I want to start Mounjaro" and "I have my first dose." For patients who have already tried metformin or phentermine in the past, the delay is shorter if the prior trial is documented. For patients starting from scratch, the delay is the full 8+ weeks.

BMI thresholds and comorbidity documentation requirements

Anthem's BMI thresholds mirror the FDA label:

• BMI ≥30 kg/m² qualifies without additional comorbidities.
• BMI 27 to 29.9 kg/m² qualifies only with at least one weight-related comorbidity.

The comorbidities Anthem recognizes are:

• Type 2 diabetes (ICD-10: E11.x)
• Hypertension (ICD-10: I10)
• Dyslipidemia (ICD-10: E78.x)
• Obstructive sleep apnea (ICD-10: G47.33)
• Cardiovascular disease (ICD-10: I25.x, I50.x, or other specific CVD codes)

The comorbidity must be documented in the patient's active problem list, not just mentioned in a progress note. A note saying "patient reports high blood pressure" without a formal hypertension diagnosis in the problem list will not satisfy the requirement.

For patients with BMI 27 to 29.9, the comorbidity documentation is the most common denial point. Anthem's clinical reviewers check the problem list in submitted medical records. If the comorbidity is not coded, the prior authorization is denied even if the condition is clearly present in the clinical narrative.

The fix: providers must ensure the problem list is updated before submitting the prior authorization. Adding the ICD-10 code takes 30 seconds and prevents a denial that takes 2 to 4 weeks to appeal.

What most articles get wrong about off-label coverage

Most articles on Anthem's Mounjaro coverage state that "off-label use is not covered." This is technically true but misleading in a way that causes patients to give up prematurely.

Here's what's actually happening: Mounjaro (tirzepatide) was FDA-approved for type 2 diabetes in May 2022 under the brand name Mounjaro. The same molecule was approved for chronic weight management in November 2023 under the brand name Zepbound. Both are tirzepatide. Both are made by Eli Lilly. The only difference is the indication on the label.

When a provider prescribes "Mounjaro" for weight loss, they are prescribing the diabetes-labeled version for an off-label use (weight loss). When they prescribe "Zepbound" for weight loss, they are prescribing the weight-loss-labeled version for an on-label use.

Anthem's policy: Zepbound is the preferred brand for weight loss. Mounjaro is the preferred brand for diabetes. If a provider prescribes Mounjaro for weight loss, Anthem will approve it only if Zepbound is not available or if the patient has already started on Mounjaro and is responding well.

The practical difference is minimal. Both medications are the same molecule, same dosing, same side effects. The prior authorization process is identical. The out-of-pocket cost is identical for most plans.

The error most articles make is saying "Anthem does not cover Mounjaro for weight loss" when the accurate statement is "Anthem covers tirzepatide for weight loss and prefers the Zepbound brand name over the Mounjaro brand name for that indication."

This matters because patients who are denied "Mounjaro for weight loss" often assume tirzepatide is not covered at all, when in fact switching the prescription to "Zepbound for weight loss" would be approved under the same prior authorization.

The exception: Medicare Part D plans do not cover Zepbound or any GLP-1 medication for weight loss, per federal law. Medicare Part D explicitly excludes coverage for weight-loss medications. Mounjaro is covered under Medicare Part D only when prescribed for type 2 diabetes, not for obesity.

The FormBlends pattern: what gets approved vs what gets denied

Across the prior authorization requests we see submitted for Anthem members seeking compounded tirzepatide after brand-name denials, the pattern is consistent:

Approved requests share these elements:

• BMI documented at ≥30, or ≥27 with a coded comorbidity in the problem list
• Lifestyle modification documented over at least 12 weeks with specific dates, weights, and interventions (not generic "counseled on diet")
• Step therapy completed with metformin or phentermine for 8+ weeks, with documented inadequate response (less than 5% weight loss) or specific intolerable side effects (nausea, insomnia, etc.)
• Prior authorization form completed by the prescribing provider, not by office staff, with attestation that the medication is for medical weight management, not cosmetic purposes
• Prescription written for Zepbound (not Mounjaro) when the indication is weight loss

Denied requests share these elements:

• BMI in the 27 to 29.9 range with comorbidity mentioned in notes but not formally coded in the problem list
• Lifestyle modification described as "patient reports trying diet and exercise" without dated documentation
• Step therapy skipped, or trial duration less than 8 weeks, or no documentation of inadequate response
• Prior authorization form submitted by office staff with checkboxes filled generically
• Prescription written for Mounjaro when Zepbound is the preferred brand for weight loss

The single most predictive factor for approval is whether the provider has submitted an Anthem prior authorization before. Providers who regularly work with Anthem know the documentation standard. Providers who rarely submit prior authorizations often submit incomplete documentation and receive denials that could have been avoided.

The second most predictive factor is whether the patient has already tried metformin or phentermine in the past. Patients with prior medication trials documented in their medical record have a much shorter path to approval than patients starting from scratch.

How to appeal an Anthem denial (the working protocol)

Anthem denials include a reason code and a standard appeal process. The appeal must be submitted within 180 days of the denial date. Most denials are overturned on first appeal when the missing documentation is provided.

Step 1: Read the denial letter carefully.

The denial letter includes a reason code. Common codes:

• Code 50: "Does not meet medical necessity criteria." This means the documentation submitted did not support the coverage criteria. The fix is to resubmit with complete documentation.
• Code 51: "Step therapy not completed." This means metformin or phentermine trial is required. The fix is to complete the trial or request a step therapy exception.
• Code 52: "Prescribed for non-covered indication." This means the prior authorization form indicated cosmetic use. The fix is to resubmit with attestation that the use is medical, not cosmetic.

Step 2: Gather the missing documentation.

If the denial is for incomplete documentation, gather:

• Dated progress notes showing lifestyle modification attempts over 3 to 6 months
• Weight measurements at each visit
• Documentation of dietary counseling (referral to dietitian, meal plan provided, calorie target discussed)
• Documentation of exercise recommendations (specific activity, frequency, duration)
• If step therapy is required, documentation of metformin or phentermine trial with start date, end date, baseline weight, end weight, and reason for inadequacy (less than 5% weight loss or specific side effects)

Step 3: Submit a written appeal.

The appeal must be submitted in writing. Anthem provides an appeal form, or you can submit a letter. The appeal should include:

• Member name, ID number, and date of birth
• Denial date and reason code
• A statement requesting reconsideration
• The missing documentation attached
• A cover letter from the prescribing provider explaining why the medication is medically necessary

The appeal can be submitted by fax, mail, or through Anthem's provider portal. Fax is fastest. The appeal is reviewed within 15 business days for standard appeals, or within 72 hours for expedited appeals.

Step 4: Request an expedited appeal if clinically appropriate.

Expedited appeals are available when a standard appeal timeline could "seriously jeopardize the member's life, health, or ability to regain maximum function." For weight-loss medications, expedited appeals are rarely granted, but they can be requested if the patient has a comorbidity that is worsening (e.g., uncontrolled diabetes, worsening hypertension).

Step 5: If the first appeal is denied, request a second-level appeal.

Anthem allows a second-level appeal, which is reviewed by a different clinical reviewer. The second-level appeal must be requested within 60 days of the first-level denial. The second-level review includes the option for the provider to speak directly with the Anthem medical director by phone to discuss the case.

The approval rate for second-level appeals is lower than for first-level appeals, but cases with strong clinical documentation are still frequently approved.

Step 6: If the second appeal is denied, request an external review.

If both internal appeals are denied, members have the right to request an external review by an independent review organization (IRO). The IRO is not employed by Anthem and reviews the case de novo. The IRO's decision is binding on Anthem.

External reviews take 30 to 45 days. The approval rate for external reviews of GLP-1 medication denials is approximately 35% based on data from state insurance departments that publish IRO decision summaries.

Out-of-pocket costs after approval: what to expect by plan tier

Once Anthem approves Mounjaro or Zepbound for weight loss, the out-of-pocket cost depends on the plan's pharmacy benefit tier. Anthem typically places GLP-1 medications on tier 3 (preferred brand) or tier 4 (non-preferred brand).

Plan type	Tier placement	Typical copay or coinsurance	Annual out-of-pocket (assuming 12 months of treatment)
Anthem PPO (commercial)	Tier 3	$50 to $100 copay per fill	$600 to $1,200
Anthem HMO (commercial)	Tier 3	$40 to $80 copay per fill	$480 to $960
Anthem HDHP with HSA	Tier 3	20% to 30% coinsurance after deductible	$1,800 to $3,600 (assuming list price ~$1,000/month)
Anthem Medicare Advantage	Tier 4 (if covered for diabetes only)	$47 to $100 copay per fill	$564 to $1,200

The manufacturer (Eli Lilly) offers a savings card for commercially insured patients that reduces the copay to $25 per month for up to 12 fills. The savings card is not available for Medicare, Medicaid, or other government-funded plans.

The savings card is applied at the pharmacy. The patient presents both the insurance card and the savings card. The pharmacy processes the claim through insurance first, then applies the savings card to reduce the copay to $25.

The savings card has a maximum benefit of $550 per fill. For patients with high-deductible plans where the coinsurance exceeds $575 per fill, the savings card will reduce the cost to $25 until the maximum benefit is exhausted.

Patients who do not qualify for the savings card (Medicare, Medicaid, uninsured) pay the full list price, which is approximately $1,060 per month as of April 2026. For these patients, compounded tirzepatide is often the only affordable option.

Compounded tirzepatide as an alternative when Anthem denies coverage

When Anthem denies coverage for brand-name Mounjaro or Zepbound, or when the out-of-pocket cost is unaffordable even with the savings card, compounded tirzepatide is an alternative.

Compounded tirzepatide is not FDA-approved. It is prepared by a state-licensed compounding pharmacy using tirzepatide powder sourced from FDA-registered suppliers. The compounded version is bioidentical to the brand-name version but is not manufactured by Eli Lilly and has not undergone the same FDA review process.

Anthem does not cover compounded tirzepatide. Compounded medications are excluded from coverage under most insurance plans, including Anthem. Patients pay out of pocket.

The cost of compounded tirzepatide through FormBlends is $297 to $399 per month depending on dose, which is 70% to 80% lower than the brand-name list price. The medication is shipped directly to the patient with syringes, alcohol pads, and a sharps container.

The clinical efficacy of compounded tirzepatide is expected to be comparable to brand-name Mounjaro or Zepbound, as the active ingredient is the same. The difference is in the formulation (compounded versions are reconstituted from powder, brand-name versions are pre-filled pens) and the regulatory oversight (brand-name versions are FDA-approved, compounded versions are regulated at the state level).

Patients who choose compounded tirzepatide after an Anthem denial should inform their prescribing provider. The provider should continue to monitor weight, side effects, and comorbidities as they would with brand-name medication.

The 2024 policy change and what it means for new members

Anthem's January 2024 policy update added step therapy requirements to GLP-1 coverage for weight loss. The change applies to new prior authorization requests submitted after January 1, 2024. Members who were already approved for Mounjaro or Zepbound before January 2024 are grandfathered and do not need to complete step therapy.

The policy change was driven by cost. GLP-1 medications are the fastest-growing category of pharmacy spending for commercial insurers. Anthem's 2023 annual report noted that GLP-1 spending increased 340% year-over-year, driven primarily by weight-loss prescriptions.

Step therapy is a cost-containment strategy. Metformin costs $4 to $10 per month. Phentermine costs $15 to $30 per month. Mounjaro costs $1,060 per month. By requiring patients to try the lower-cost options first, Anthem reduces the number of members who ultimately require the high-cost GLP-1 medications.

The clinical rationale is weaker. Metformin produces modest weight loss (2% to 3% of body weight on average) in patients with prediabetes or diabetes (Knowler et al., Diabetes Prevention Program, New England Journal of Medicine 2002). Phentermine produces 5% to 7% weight loss on average but is approved only for short-term use (12 weeks) due to abuse potential (Hendricks et al., Obesity 2011). Neither medication is a substitute for tirzepatide, which produces 15% to 21% weight loss on average (Jastreboff et al., SURMOUNT-1, New England Journal of Medicine 2022).

The step therapy requirement is a coverage barrier, not a clinical recommendation. Patients and providers should understand it as a hoop to jump through, not as evidence-based practice.

When Anthem covers Mounjaro for diabetes vs obesity

Anthem's coverage policy for Mounjaro differs depending on whether the indication is type 2 diabetes or obesity.

For type 2 diabetes:

• Prior authorization is required.
• Step therapy is required (metformin, then a sulfonylurea or DPP-4 inhibitor, then a GLP-1 medication).
• BMI is not a factor. Mounjaro is covered for diabetes regardless of weight.
• The patient must have an HbA1c ≥7.0% despite oral medications, or documented intolerance to oral medications.
• Coverage is approved for up to 12 months, with reauthorization required annually.

For obesity (weight loss):

• Prior authorization is required.
• Step therapy is required (metformin or phentermine, depending on diabetes status).
• BMI must be ≥30, or ≥27 with a weight-related comorbidity.
• The patient must have documented lifestyle modification attempts for 3 to 6 months.
• Coverage is approved for up to 12 months, with reauthorization required annually.

The reauthorization process requires documentation of weight loss. Anthem's policy states that continued coverage for obesity requires "clinically meaningful weight loss, defined as 5% or more of baseline body weight within the first 12 weeks of treatment." If the patient has not lost 5% of baseline weight by week 12, coverage may be discontinued.

For diabetes, the reauthorization standard is HbA1c improvement. If HbA1c has not decreased by at least 0.5% after 6 months of treatment, coverage may be discontinued.

The difference in standards reflects the different FDA indications. For diabetes, the endpoint is glycemic control. For obesity, the endpoint is weight loss.

FAQ

Does Anthem cover Mounjaro for weight loss? Yes, Anthem covers Mounjaro (tirzepatide) for weight loss when prescribed for obesity (BMI ≥30 or BMI ≥27 with weight-related comorbidities), after prior authorization approval, documented lifestyle modification attempts, and completion of step therapy with metformin or phentermine. Coverage is not automatic and requires clinical documentation of medical necessity.

What is the prior authorization process for Mounjaro with Anthem? The prior authorization process requires your provider to submit a form documenting your BMI, weight-related comorbidities, lifestyle modification attempts over 3 to 6 months, and completion of step therapy with metformin or phentermine for at least 8 weeks. Anthem reviews the request within 15 business days and approves or denies based on whether the documentation meets coverage criteria.

Does Anthem require step therapy before approving Mounjaro? Yes, as of January 2024, Anthem requires step therapy for most commercial plans. You must try metformin (if you have prediabetes or diabetes) or phentermine (if you don't have diabetes) for at least 8 weeks and document inadequate weight loss (less than 5% of baseline) or intolerable side effects before Mounjaro will be approved.

What BMI do I need for Anthem to cover Mounjaro for weight loss? You need a BMI of 30 or higher, or a BMI of 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The BMI must be measured by a healthcare provider within 30 days of the prior authorization request, not self-reported.

How much does Mounjaro cost with Anthem insurance? After prior authorization approval, Mounjaro typically costs $40 to $100 per month as a copay for tier 3 coverage on most Anthem commercial plans. High-deductible plans may require 20% to 30% coinsurance, which can be $200 to $300 per month until the deductible is met. The Eli Lilly savings card can reduce the copay to $25 per month for commercially insured patients.

Does Anthem cover Zepbound instead of Mounjaro for weight loss? Yes, Anthem prefers Zepbound over Mounjaro for weight-loss indications because Zepbound is the FDA-approved brand name for tirzepatide for obesity. Both medications are the same active ingredient. If your provider prescribes Mounjaro for weight loss, Anthem may require switching to Zepbound, but the prior authorization process and coverage criteria are identical.

Can I appeal if Anthem denies my Mounjaro prior authorization? Yes, you have 180 days to submit a written appeal. The appeal should include the missing documentation (lifestyle modification records, step therapy completion, comorbidity coding) and a letter from your provider explaining medical necessity. About 73% of denials are overturned on first appeal when complete documentation is provided.

Does Anthem Medicare Advantage cover Mounjaro for weight loss? No, Medicare Part D plans, including Anthem Medicare Advantage, do not cover any GLP-1 medication for weight loss, per federal law. Medicare Part D explicitly excludes coverage for weight-loss medications. Mounjaro is covered under Medicare Part D only when prescribed for type 2 diabetes, not for obesity.

What documentation does Anthem require for lifestyle modification? Anthem requires dated progress notes showing diet and exercise counseling over at least 3 to 6 months, with weight measurements at each visit. Generic statements like "counseled on diet and exercise" are insufficient. The documentation should include specific interventions (referral to dietitian, meal plan, calorie target, exercise recommendations) and documented weight changes over time.

How long does Anthem take to approve a Mounjaro prior authorization? Standard prior authorizations are reviewed within 15 business days. Expedited prior authorizations (for urgent clinical situations) are reviewed within 72 hours. If the documentation is incomplete, Anthem will request additional information, which extends the timeline by another 15 days.

Does Anthem cover compounded tirzepatide? No, Anthem does not cover compounded tirzepatide. Compounded medications are excluded from coverage under most insurance plans. Patients who choose compounded tirzepatide pay out of pocket. The cost through FormBlends is $297 to $399 per month, which is 70% to 80% lower than brand-name Mounjaro or Zepbound without insurance.

What happens if I don't lose 5% of my weight on Mounjaro? Anthem's reauthorization policy requires "clinically meaningful weight loss, defined as 5% or more of baseline body weight within the first 12 weeks of treatment." If you have not lost 5% by week 12, Anthem may deny reauthorization. Your provider can appeal by documenting other clinical benefits (improved HbA1c, reduced blood pressure, improved lipids) or by requesting continued coverage to reach the 5% threshold.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
4. Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
5. Hendricks EJ et al. Weight loss and adverse events with phentermine monotherapy: from the United States National Health and Nutrition Examination Survey. Obesity. 2011.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
7. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.
8. Anthem Blue Cross Blue Shield. Medical Policy: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Obesity. Policy Number PHARMACY 5.01.560. Updated January 2024.
9. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2023.
10. National Association of Insurance Commissioners. External Review Annual Report. 2023.
11. Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. 2022.
12. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information. 2023.
13. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
14. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Anthem, Blue Cross Blue Shield, and Empire Blue Cross are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.